JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Case Report
Get two with one: bevacizumab treatment in hereditary hemorrhagic telangiectasia with concomitant cirrhosis
Abstract
Hereditary hemorrhagic telangiectasia (HHT) or Osler-Weber-Rendu syndrome is a birth defect of the blood vessels that causes telangiectasias and arteriovenous malformations. HHT is a rare, autosomal dominant vascular disorder affecting approximately 1 in 8000 people. This multisystem angiogenic disorder is genetically and phenotypically variable, with the most common symptom being severe and recurrent epistaxis. ALK1, TGF-ß, and VEGF are involved in its pathogenesis. VEGF increases mitotic activity in vascular endothelial cells, leading to uncontrolled angiogenesis and the formation of fragile vessels. Bevacizumab is used in the treatment of HHT by inhibiting VEGF. We present our patient, who developed hepatic encephalopathy due to hemorrhages with diffuse telangiectasias of the skin and tongue due to HHT and achieved an effective response to both conditions with bevacizumab.

Keywords : Bevacizumab, hereditary hemorrhagic telangiectasia, Osler-Weber-Rendu syndrome, telangiectasia

Download Article


1. Fleagle JM, Bobba RK, Kardinal CG, Freter CE. Iron deficiency anemiarelated to hereditary hemorrhagic telangiectasia: response to treatmentwith bevacizumab. Am J Med Sci. 2012;343(3):249-251.
2. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagictelangiectasia have increased plasma levels of vascular endothelialgrowth factor and transforming growth factorbeta1 as well as highALK1 tissue expression. Haematologica. 2005;90(6):818-928.
3. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagictelangiectasia. N Engl J Med. 2009;360(20):2143-2144.
4. Oosting S, Nagengast W, de Vries E. More on bevacizumab inhereditary hemorrhagic telangiectasia. N Engl J Med. 2009;361(9):931.
5. Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patientswith hereditary hemorrhagic telangiectasia and severe hepatic vascularmalformations and high cardiac output. JAMA. 2012;307(9):948-955.
6. Epperla N, Hocking W. Blessing for the bleeder: bevacizumab inhereditary hemorrhagic telangiectasia. Clin Med Res. 2015;13(1):32-35.doi: 10.3121/cmr.2013.1205
Article available in :
Volume 2, Issue 1, 2024
Page : 20-21
https://doi.org/10.51271/JCHOR-0030
Article Information
Received : 19 Ara 2023
Accepted : 04 Oca 2024
Published : 12 Şub 2024
Corresponding Author :

Serhat Çelik: Department of Hematology, Yenimahalle Training and Research Hospital, Ankara, Turkiye

[email protected]
Citation : Çelik S, Kaynar L. Get two with one: bevacizumab treatment in hereditary hemorrhagic telangiectasia with concomitant cirrhosis. J Curr Hematol Oncol Res. 2023; 1(1): 15-17.

Read: 1165
Download : 485
Cited: 0
_Footer